Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Lead-in Cohort • To assess the safety and tolerability of PF-04449913 in patients with primary or secondary MF who have been previously treated with ≥1 JAKi. Randomized Cohort • To compare the effect of PF-04449913 vs. placebo on SVR in patients with primary or secondary MF who have been previously treated with ruxolitinib.
Critère d'inclusion
- Myelofibrosis